Is Aytu stock a buy or sell?
Mar 03, 2022 · AYTU stock is falling after announcing a public offering. What value AYTU BioPharma has been giving? Aytu BioPharma is a drug organization with an arrangement of business remedy therapeutics and customer wellbeing items, and a developing therapeutics pipeline zeroed in on treating interesting, pediatric-beginning issues.
What do you think about the Aytu collapse price?
Find the latest Aytu BioPharma, Inc. (AYTU) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
Why did Aytu Biopharma stock see a gap up Tuesday morning?
Apr 03, 2022 · Aytu Biopharma's stock was trading at $1.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AYTU shares have decreased by 25.9% and is now trading at $1.00.
Is Aytu Biopharma's (ATU) PE ratio good or bad?
Aytu BioPharma Inc () Stock Market info Recommendations: Buy or sell Aytu BioPharma stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Aytu BioPharma share forecasts, stock quote and buy / sell signals below.According to present data Aytu BioPharma's AYTU shares and potentially its market environment have been in bearish cycle …
Is AYTU stock a good buy?
Is AYTU BIOPHARMA Stock a good buy in 2022, according to Wall Street analysts? The consensus among 2 Wall Street analysts covering (NASDAQ: AYTU) stock is to Strong Buy AYTU stock.
Will AYTU go up?
Cantor Fitzgerald is very positive about AYTU and gave it a "" rating on Mar 30, 2021. The price target was changed from 7.42 to 0.93....Predicted Opening Price for Aytu Bioscience of Tuesday, April 12, 2022.Fair opening price April 12, 2022Current price$0.92$0.92 (Undervalued)
What happened AYTU BioScience?
(NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the closing of its merger with Neos Therapeutics (previously trading on Nasdaq under "NEOS").Mar 22, 2021
Is AYTU a good company?
Aytu BioScience Reviews FAQs Is Aytu BioScience a good company to work for? Aytu BioScience has an overall rating of 2.9 out of 5, based on over 26 reviews left anonymously by employees. 37% of employees would recommend working at Aytu BioScience to a friend and 38% have a positive outlook for the business.
Is AYTU Bioscience a buy?
Aytu Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Is AYTU FDA approved?
(Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced on December 13, 2021, that the U.S. Food and Drug Administration (FDA) has cleared the IND application for AR101/enzastaurin, enabling the company to proceed with initiating a pivotal ...Dec 15, 2021
When did AYTU go public?
May 2016In May 2016, we conducted a public offering of our common stock and warrants from which we received net cash proceeds of approximately $6.6 million.
Did AYTU reverse split?
(“the Company” or “Aytu”) Board of Directors approved a 1-for-10 reverse stock split of the Company's common stock, which will be effective at 8:00 a.m. Eastern Time on Tuesday, December 8, 2020. The Company's stockholders approved the reverse stock split at an Annual Meeting of Stockholders on April 23, 2020.Dec 8, 2020
Is Aytu Biopharma a buy right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aytu Biopharma in the last year. There are currently 2 buy rating...
How has Aytu Biopharma's stock price been impacted by Coronavirus?
Aytu Biopharma's stock was trading at $1.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization...
When is Aytu Biopharma's next earnings date?
Aytu Biopharma is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022. View our earnings forecast for Aytu Biop...
How were Aytu Biopharma's earnings last quarter?
Aytu Biopharma, Inc. (NASDAQ:AYTU) released its quarterly earnings data on Sunday, February, 13th. The company reported ($0.44) earnings per share...
When did Aytu Biopharma's stock split? How did Aytu Biopharma's stock split work?
Shares of Aytu Biopharma reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number o...
What price target have analysts set for AYTU?
2 Wall Street analysts have issued 12 month price targets for Aytu Biopharma's shares. Their forecasts range from $11.00 to $14.50. On average, the...
Who are Aytu Biopharma's key executives?
Aytu Biopharma's management team includes the following people: Joshua R. Disbrow , Chairman & Chief Executive Officer Jarrett T. Disbrow , Exec...
Who are some of Aytu Biopharma's key competitors?
Some companies that are related to Aytu Biopharma include Fortress Biotech (FBIO) , Lipocine (LPCN) , ProMetic Life Sciences (PFSCF) , Longever...
What other stocks do shareholders of Aytu Biopharma own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu Biopharma investors own include Sorrento Therapeutics...
"Should I invest in Aytu BioPharma stock?" "Should I trade "AYTU" stock today?"
According to our live Forecast System, Aytu BioPharma Inc stock is an awesome long-term (1-year) i...
What is the Aytu BioPharma stock price / share price today?
The Aytu BioPharma stock price is 1.240 USD today.
Will Aytu BioPharma stock price grow / rise / go up?
Yes. The AYTU stock price can go up from 1.240 USD to 2.003 USD in...
Is it profitable to invest in Aytu BioPharma stock?
Yes. The long-term earning potential is + 61.55 % in one year.
Will AYTU stock price fall / drop?
No. See above .
What will Aytu BioPharma stock price be worth in five years (2027)?
The AYTU ("AYTU" ) future stock price will be 3.976 USD .
Will AYTU stock price crash?
According to our analysis, this will not happen.
Will Aytu BioPharma stock price hit 10 USD price in a year?
Not within a year. See above .
Will Aytu BioPharma stock price hit 20 USD price in a year?
Not within a year. See above .
Signals & Forecast
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Aytu Bioscience stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock.
Is Aytu Bioscience stock A Buy?
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Is Aytu Biopharma a buy right now?
Aytu Bioscience holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
What stocks does MarketBeat like better than Aytu Biopharma?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aytu Biopharma stock.#N#View analyst ratings for Aytu Biopharma or view top-rated stocks.
When is Aytu Biopharma's next earnings date?
Wall Street analysts have given Aytu Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aytu Biopharma wasn't one of them.
How were Aytu Biopharma's earnings last quarter?
Aytu Biopharma is scheduled to release its next quarterly earnings announcement on Monday, September 13th 2021.#N#View our earnings forecast for Aytu Biopharma.
How has Aytu Biopharma's stock price been impacted by Coronavirus?
Aytu Biopharma, Inc. (NASDAQ:AYTU) announced its earnings results on Sunday, May, 16th. The company reported ($1.41) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $1.05. The company earned $13.48 million during the quarter, compared to analysts' expectations of $14.10 million.
When did Aytu Biopharma's stock split? How did Aytu Biopharma's stock split work?
Aytu Biopharma's stock was trading at $1.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AYTU stock has increased by 164.4% and is now trading at $3.57.#N#View which stocks have been most impacted by COVID-19.
What price target have analysts set for AYTU?
Aytu Biopharma's stock reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017.
AYTU Target Price
2 brokers have issued 12 month price objectives for Aytu Biopharma's shares. Their forecasts range from $11.00 to $14.50. On average, they expect Aytu Biopharma's stock price to reach $12.75 in the next year.
Aytu BioPharma Inc ( AYTU ) Stock Market info
AYTU price target in 14 days: 3.827 USD* upside and 3.262 USD* downside. (Highest and lowest possible predicted price in a 14 day period)
How much revenue did Aytu make in Q4?
Recommendations: Buy or sell Aytu BioPharma stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Aytu BioPharma share forecasts, stock quote and buy / sell signals below.
What is Aytu Biopharma?
Aytu reported Q4 results in October that beat estimates across the board with revenue of $14.86 million, surpassing the $11.24 million revenue analysts were projecting. A careful review of the data supp...
Executive Summary
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment ...
Share Price & News
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. More Details
Valuation
How has Aytu Biopharma's share price performed over time and what events caused price changes?
Future Growth
Is Aytu Biopharma undervalued compared to its fair value and its price relative to the market?
Dividend
How is Aytu Biopharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Management
What is Aytu Biopharma current dividend yield, its reliability and sustainability?
Ownership
How experienced are the management team and are they aligned to shareholders interests?
Who is the CEO of Aytu Biopharma?
Who are the major shareholders and have insiders been buying or selling?
Who is covering NEOS?
Article continues below advertisement. The combined company will operate under Aytu Biopharma and the ticker symbol “AYTU.”. Aytu BioScience CEO Josh Disbrow will continue to lead the combined company, while NEOS CEO Jerry McLaughlin will join the entity’s board of directors.
Aytu BioPharma Inc. (AYTU)
According to MarketBeat, NEOS stock is also covered by just one Wall Street analyst—JPM Securities. The analyst has a market perform rating on the stock. However, JPM didn’t provide a target price for NEOS stock.
Aytu BioPharma Inc. - Hold
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Chart for AYTU
Zacks' proprietary data indicates that Aytu BioPharma Inc. is currently rated as a Zacks Rank 3 and we are looking for an inline return from the AYTU shares relative to the market in the next few months. In addition, Aytu BioPharma Inc.
